- Transitional cell bladder cancer
- Invasive bladder cancer
- Superficial bladder cancer
- Squamous cell bladder cancer
- Other rare types
Bladder Cancer Treatment Market size was valued at 3.6 billion in 2022 and is expected to reach 4.8 billion by 2029, at a CAGR of 4.3% from 2023 to 2029. Bladder cancer is a disease in which malignant cells are formed in the tissues of the bladder. Symptoms of bladder cancer include blood in the urine, pain with urination, and low back pain. There are three types of bladder cancer that begin in the cells in the lining of the bladder. They are named transitional cell carcinoma, squamous cell carcinoma, and adenocarcinoma. As per the National Institute of Health, approximately 17,000 women and 45,000 men every year are diagnosed with bladder cancer in the U.S. only. The market for bladder cancer is rapidly increasing and it is anticipated to grow rapidly from 2016 to 2022 globally. According to The American Cancer Society, in 2017, estimated bladder cancers in the United States 79,030 new cases (about 60,490 in men and 18,540 in women) were diagnosed, and about 16,870 deaths from bladder cancer (about 12,240 in men and 4,630 in women). Bladder cancer accounts for about 5% of all new cancers in the US. It is the fourth most common cancer in men, but it is less common in women. In addition, the rise in awareness about bladder cancer and its available treatment options in the market, innovation in drug development, and subsequent technological advancements are expected to drive the market for bladder cancer treatment drugs. An increasing number of mergers and acquisitions, the rise in the number of collaborations and partnerships, new product launches, and growing awareness about the availability of bladder cancer treatment drugs are some of the latest trends that have been observed in the market.
Fastest Growing Market
Increase in incidence rate of bladder cancer cases, technological advancements, drug innovations with regard to the treatment of bladder cancer, government initiatives, the rise in aging of the population, and advanced health care services are expected to drive the market for bladder cancer treatment drugs. In addition, the rise in awareness about bladder diseases, their available therapies in the market, and increase in health care expenditure are driving the global market for bladder cancer treatment drugs. However, the rise in a number of patent expirations, asymptomatic nature of the disease, and rise in the use of generic drugs are some of the major factors restraining the revenue growth of the global bladder cancer treatment drugs market over the forecast period.
The bladder cancer treatment market key players are: AstraZeneca plc (U.K.), Bristol-Myers Squibb (U.S.), Celgene Corporation (U.S.), Eli Lilly and Company (U.S.), F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Pfizer Inc.( U.S.), Sanofi (France)
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.